- Imricor Medical Systems (IMR) signs an agreement with MiRTLE Medical for its 12-lead ECG system
- Under the terms of the new sales distribution agreement, Imricor will be a non-exclusive distributor of MiRTLE’s MRI-compatible, 21-lead ECG system
- Imricor says it recognised long ago that 12-lead ECG in the MRI environment was important to its strategic plan
- Imricor Medical Systems closed down 2.45 per cent at $1.20 on September 27
Imricor Medical Systems (IMR) has signed an agreement with MiRTLE Medical for its 12-lead ECG system.
Imricor is a developer of MRI-compatible medical devices which can be used to carry out MRI-guided cardiac catheter ablation procedures, with the intent of enabling higher success rates, along with faster and safer treatments compared to conventional procedures using x-ray guided catheters.
Under the terms of the new sales distribution agreement, Imricor will be a non-exclusive distributor of MiRTLE’s MRI-compatible, 21-lead ECG system.
“This is a pivotal moment for us, as we move beyond product development and begin providing our 12-lead ECG system to physicians for clinical use,” President and CEO of MiRTLE Medical James Robertson said.
Imricor has been working with MiRTLE on the technical aspects of interfacing its 12-lead ECG system with its Advantage-MR EP Recorder and Stimulator since October of 2017.
“We recognised long ago that 12-lead ECG in the MRI environment was important to our strategic plan of enabling iCMR-guided ablations of complex arrhythmias such as ventricular tachycardia (VT),” Imricor’s Chair and CEO Steve Wedan said.
“With this agreement, we are expanding our relationship to include sales and marketing, as we provide a channel to our customers who need the MiRTLE system.”
Imricor Medical Systems closed down 2.45 per cent at $1.20 on September 27.